Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

NDA Submission Completed for Zipalertinib + Chemo in 1L EGFR Exon 20 Ins Mutation NSCLC

November 18, 2026

FDA Fast Track Designation for Onvansertib in 1L RAS-Mutated Metastatic CRC

November 18, 2026

CRL Received from FDA for BLA Application Based on HARMONi Study of ivonescimab + platinum-containing chemo for EGFR TKI-treated NSCLC patients

November 18, 2026

Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for ccRCC Following Treatment With an Anti-PD-1/PD-L1 Therapy

November 18, 2026

FDA Accepts sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

November 18, 2026

Not Approvable Letter received from the FDA in response to PMA application for Optune Mya® in NSCLC patients with brain mets following stereotactic radiation

November 18, 2026

US FDA Clears IND Application for BD200

November 18, 2026

FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma 

November 18, 2026

Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Ph 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Announced

November 11, 2026

IND Clearance for KT-300 in for RAS-Driven Cancers Announced

November 11, 2026

FDA grants Orphan Drug Designation for Cantrixil in AML

November 11, 2026

Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

November 11, 2026

Lirafugratinib (Lyrfigtu) Added to NCCN Guidelines as 2L Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

November 11, 2026

FDA PDUFA Date for Resubmitted NDA for Rivoceranib + Camrelizumab combo in 1L Unresectable or Metastatic HCC Announced

November 11, 2026

FDA Grants Priority Review to BRUKINSA Combo in 1L MCL

November 11, 2026

Ivonescimab Receives NMPA Priority Review for 1L Biliary Tract Cancer

November 11, 2026

BLA for Etentamig submitted to US FDA for RRMM patients

November 4, 2026

FDA approves clinical trials under IND application for FMC-242 in solid tumors

November 4, 2026

FDA approves the investigator-sponsored clinical trial (IST) of HMBD-002 in combination with venetoclax and azacitidine in AML and MDS

November 4, 2026

FDA provides Feedback in Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors

October 28, 2026

FDA grants Fast Track Designation for MC001 for Pancreatic Cancer

October 28, 2026

CHMP recommends approval of TALVEY® (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

October 27, 2026

New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) accepted for review by the China NMPA

October 27, 2026

FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC

October 20, 2026

FDA granted Fast Track designation to QTX3034 + cetuximab for KRASG12D-mutant CRC, with or without FOLFOX chemotherapy

October 20, 2026
Page1 Page2 Page3 … Page59

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.